Tel: LO CALL: 1850 918 133

Ailesbury Clinic Blog

Psoriasis: Ixekizumab

The National Institute for Health and Care Excellence (NICE), in its final draft guidance issued this week, has recommended ixekizumab, an antibody that inhibits interleukin-17A, as an option for treating adults with severe plaque psoriasis that doesn’t respond to standard therapies.

The guidance recommended ixekizumab as an option for treating plaque psoriasis in adults, but only if they had severe disease (a total psoriasis area and severity index (PASI) score of 10 or more), which had not responded to standard systemic therapies such as ciclosporin or methotrexate or for patients in whom these were contraindicated or not tolerated.1

Ixekizumab is given by subcutaneous injection at a dose of 80 mg every two weeks for 12 weeks and then every four weeks. The list price is £1125 (€1300; $1370) for the 80 mg dose, but NICE has recommended that it be used only at the discounted cost agreed in a patient access scheme with the manufacturer.

The NICE draft appraisal recommended that ixekizumab be stopped after 12 weeks if a patient’s psoriasis had not responded adequately. Adequate response was defined as a 75% reduction in PASI score from when treatment started or a 50% reduction in PASI score together with a five point reduction in the dermatology life quality index.

After reviewing the available evidence the NICE appraisal committee concluded that ixekizumab was more clinically effective than placebo or etanercept (a tumour necrosis factor inhibitor) and had similar side effects to other biological treatments. The committee found that the incremental cost effectiveness ratio was within the range considered to be a cost effective use of NHS resources.

The draft guidance is out for consultation, and NHS organisations can make decisions on its use locally until it is finalised. If NICE confirms the draft recommendations the NHS must make sure it is available within three months of the final guidance being published.


1. NICE. Final appraisal determination. Ixekizumab for treating moderate to severe plaque psoriasis. March 2017.

Ailesbury Dublin

David Lloyd Riverview,

1st Floor,

Beech Hill Road,
Donnybrook  Dublin 4.

Eircode DO4 AF10 (Google Map)

Tel:   (01)269 2255 / 2133

Fax: (01) 218 0857 

Image result for femme 360




Ailesbury Cork

Holbar House  

East Village Medical Cntre

Douglas, Cork 

Eircode T12 HK2C (Google Map)

Tel:   (021) 4835006


Fax: (01) 218 0857


Image may contain: 3 people, people smiling, close-up


Botox and Migraine Lectures


Congratulations to our own Ailesbury Doctor Dr Olga O' Driscoll coming 1st out of 100 doctors in the St. Mary's Diploma in Aesthetic Medicine and securing a mentorship under Dr. Adriano Santorelli in Naples.



Specialists in Dermatology and Aesthetic Medicine. We perform minor surgery + skin cancer screen. VHI, Aviva, Laya and Irish Health accepted. Hstopathology is covered by private insurance and performed by dedicated skin histopathologists at St. Vincent's University Hospital, Dublin. Consultation €150  READ MORE 

Image result for vhi aviva




Image result for emergency   For Emergency Ring 086 2487464